Pt Prodia Widyahusada Tbk · IDX:PRDA
Pt Prodia Widyahusada Tbk — FY2025 Earnings Presentation
20 slides from Pt Prodia Widyahusada Tbk's earnings presentation, March 2026
Slide 1: FY2025 Company Updates
FY2025 Company Updates PT Prodia Widyahusada Tbk | PRDA.JK
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by PT Prodia Widyahusada (the "Company") solely for use in connection with the analyst presentation relating to the Company. The information contained in this presentation is strictly confidential and is provided to you solely for your reference. By vie
Slide 3: Company Overview
Company Overview
Slide 4: FY2025 Key Highlights
FY2025 Key Highlights The largest private independent clinical lab chain with 40.0%* market share in Indonesia Starting from 2025, Prodia expand networks through strategic IDR 2.28 Trillion Current Initiatives collaboration in SEA Market and optimalization of clinical services USD 136 Million FY2025
Slide 5: Continuous Improvement in a Challenging Market
Continuous Improvement in a Challenging Market Ensure sustainability business with innovation, growth, and optimization Visits Revenue (in Million) (in IDR Trillion) CAGR* CAGR* >3.0 2.3 -1.8% 4.0% >2.7 1.9 Prodia has strengthen the fundamental and generated continuous 2020 2021 2022 2023 2024 2025
Slide 6: Business Highlight
J be? Business Highlight
Slide 7: The Comprehensive Center of Excellence
The Comprehensive Center of Excellence Delivering personalization and precision in multiple customer segment Routine Testing Non-Laboratory Testing Specialty Clinics Esoteric Testing Referral Lab Services Doctor Consultation General Medical Preventive Treatment One-stop shop, Multiomic Testing Check
Slide 8: Scalable Hub and Spoke Business Model
Scalable Hub and Spoke Business Model Centralized core operations (hub) while efficiently distributing services through multiple outlets (spokes) 4 Referral Labs in Jakarta, Surabaya, Medan, Makassar Significant Economies of Scale Achieved Hub and spoke model offers Centralized information scalable
Slide 9: Maintain Strong and Long-Term Relationship
Maintain Strong and Long-Term Relationship Generate new tests and ongoing referrals in partnership with medical & scientific community Strong relationships through the work Introduced new tests, such as NIPT ProSafe, CArisk, of more than 500 Marketing and DIArisk, New Born Screening, Sleep & Stress
Slide 10: Be The Next Generation Laboratory
Be The Next Generation Laboratory To deliver precision medicine with comprehensive lab services Research Evaluation Laboratory Laboratory Mass Spectrometry & Molecular Predictive & Separation Science Diagnostic Laboratory Laboratory Next Generation Laboratory Anatomical Pathology Cancer Molecular La
Slide 11: Business Updates
Business Updates
Slide 12: Expand Our Presence with Diverse Models
Expand Our Presence with Diverse Models With strategic expansion of outlets, ensuring proximity to our customers 2024 2025 Digital Platform Optimization 2026 Outlet Development Target >3 Hospital Labs Management 354 402 Outlets Outlets includes hospital lab & genomic site U by Prodia > 20 POC Outlet
Slide 13: Financial Updates
Financial Updates
Slide 14: Soft Performance in 2025 Revenue
Soft Performance in 2025 Revenue Due to softer healthcare demand and challenges in corporate clients Revenue (Audited) Quarterly Revenue (Audited) In IDR Billion In IDR Billion FY20-FY25 CAGR +4.0% 2020 2021 2022 2023 2024 2025 FY24-FY25 • FY25 revenue mostly Growth: +1.3% 701 driven by Walk-In 2,65
Slide 15: 2025 Financial Performance
2025 Financial Performance Margins affected by rising raw material costs, IT investments, and operating expenses as the company strengthens its long-term capabilities. COGS Gross Profit OPEX Net Income in IDR Billion in IDR Billion In IDR Billion In IDR Billion FY20-FY25 CAGR +2.8% FY20-FY25 CAGR +5
Slide 16: FY2025 Financial Summary
FY2025 Financial Summary Revenue grew in FY25 despite margin pressure, while Prodia maintains a strong balance sheet and low leverage to support future growth. (in IDR Bn) FY2025 FY2024 Change Revenue 2,281.7 2,252.2 +1.3% Gross Profit 1,332.7 1,352.0 -1.4% EBIT 225.2 300.5 -25.1% EBT 264.3 343.0 -2
Slide 17: Our Professional Team & Shares Information
Our Professional Team & Shares Information
Slide 18: Experienced & Professional Management Team
Experienced & Professional Management Team With more than 20 years experience in delivering growth and innovation of Prodia 53 Years of 53 Years of 42 Years of 51 Years of 34 Years of Experience Experience Experience Experience Experience Gunawan Endang Joseph Fellipus KeriLestari Keri Lestari Andi
Slide 19: Shareholders Composition
Shareholders Composition Public free float is 23% of total with market cap of IDR 2.05 Trillion* PT Prodia Utama Bio Majesty Pte. Ltd.** Public Treasury Stock*** 57% 15% 23% 5% 30% Distributor for Contract Research Research, therapy and medical equipment Organization banking of stem cell PT Prodia W
Slide 20: For further Information
For further Information: PT Prodia Widyahusada Tbk Prodia Tower. Jalan Kramat Raya No. 150 Jakarta 10430, Indonesia Email: investor.relation@prodia.co.id